Watermark
  Back to Search Results

BGB-A317-A1217-202

Completed

AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

BGB-A317-A1217-202

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

NCT04693234

EudraCT Number Info icon SVG graphic used for tooltips or additional information.

2020-004657-77

China Drug Trials ID Info icon SVG graphic used for tooltips or additional information.

CTR20210588

Study Overview

Sex: Female Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: Female Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan